Pharmaceutical - Pharmaceutical, North America, Pradaxa


Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth


The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

Pradaxa sNDA for DVT and PE accepted by FDA


The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin


A new perspective from the US Food and Drug Administration states the agency has not changed its recommendations…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaResearch

Boehringer Ingelheim updates safety info for Pradaxa related to heart valve


The US subsidiary of German independent drug major Boehringer Ingelheim says that the US prescribing…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Serious bleeding risk with Boehringer's Pradaxa no worse than warfarin, says FDA


In a follow up to a 2011 safety communication, the US Food and Drug Administration has evaluated new…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationResearch

Boehringer Ingelheim updates US labelling of Pradaxa for stroke


Independent German drug major Boehringer Ingelheim has updated the US prescribing information for Pradaxa…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Back to top